AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-mg/day
Number of subjects: 546
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 546
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 546
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17-beta-estradiol 0.5-mg/day
Number of subjects: 546
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 1.8 g/day
Number of subjects: 546
Study 27393470 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-extent group (SEG) - ILM peeled with a radius of 0.75 disc diameter
Number of subjects: 65
Study 27393470 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-extent group (LEG) - ILM peeled with a radius of 1.5 disc diameter
Number of subjects: 65
Study 24693945 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise twice a week for 3 months
Number of subjects: 120
Study 24693945 — intervention group
Group type: COMPARATOR
Intervention: General exercise twice a week for 3 months
Number of subjects: 120
Study 24693945 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Number of subjects: 120
Study 24693945 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 120
Study 24366025 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)-based intervention
Number of subjects: 90
Study 24366025 — intervention group
Group type: COMPARATOR
Intervention: Traditional knowledge-based intervention
Number of subjects: 90
Study 20632193 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine (20 mg/day)
Number of subjects: 447
Study 20632193 — intervention group
Group type: COMPARATOR
Intervention: famotidine (40 mg/day)
Number of subjects: 447
Study 20632193 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 447
Study 17554249 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/day elemental zinc in multivitamin syrup for 2 weeks)
Number of subjects: 56
Study 17554249 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin syrup without zinc (control)
Number of subjects: 56
Study 16640099 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T (stavudine)
Number of subjects: 600
Study 16640099 — intervention group
Group type: COMPARATOR
Intervention: tenofovir DF
Number of subjects: 600
Study 12792126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 47
Study 12792126 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 47
Study 10431556 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief education
Number of subjects: 564
Study 10431556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined education
Number of subjects: 564
Study 10431556 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional group education
Number of subjects: 564
Study 8551210 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabular memory network retrieval strategy (PRODUCT)
Number of subjects: 266
Study 8551210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontabular memory network retrieval strategy (ERROR RATE)
Number of subjects: 266
Study 8551210 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational strategy (MIN)
Number of subjects: 266
Study 8551210 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition Efficiency
Number of subjects: 266
Study 8551210 — intervention group
Group type: EXPERIMENTAL
Intervention: Speediness of information processing
Number of subjects: 266
Study 8551210 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit-span measure of Short-Term Memory
Number of subjects: 266
Study 2276389 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg once daily
Number of subjects: 12
Study 2276389 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg b.d.
Number of subjects: 12
Study 2276389 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 474478 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diet
Number of subjects: 12
Study 474478 — intervention group
Group type: COMPARATOR
Intervention: Low fiber diet
Number of subjects: 12
Study 30297735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral median nerve stimulation at low or high frequencies
Number of subjects: 0
Study 30297735 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral median nerve stimulation at interelectrode distances of 2 and 4 cm
Number of subjects: 0
Study 30297735 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the thumb on the palm side
Number of subjects: 0
Study 30297735 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of C-fibers with capsaicin
Number of subjects: 0
Study 30297735 — intervention group
Group type: COMPARATOR
Intervention: Median nerve stimulation
Number of subjects: 0
Study 26475246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid bolus administration guided by noninvasive cardiac output monitor after passive leg-raising maneuver
Number of subjects: 122
Study 26475246 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study 24553094 — intervention group
Group type: COMPARATOR
Intervention: Nitrate maintenance (n=54)
Number of subjects: 105
Study 24553094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate withdrawal followed by introduction of placebo (n=51)
Number of subjects: 105
Study 23141856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensification intravenous diuretic therapy
Number of subjects: 308
Study 23141856 — intervention group
Group type: COMPARATOR
Intervention: Low-intensification intravenous diuretic therapy
Number of subjects: 308
Study 20415693 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose combination (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Number of subjects: 0
Study 20415693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose combination (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Number of subjects: 0
Study 20415693 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose metformin (metformin 1000 mg b.i.d.)
Number of subjects: 0
Study 20415693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose metformin (metformin 500 mg b.i.d.)
Number of subjects: 0
Study 20415693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin monotherapy (sitagliptin 100 mg q.d.)
Number of subjects: 0
Study 20415693 — intervention group
Group type: COMPARATOR
Intervention: Placebo/metformin (switched to metformin monotherapy uptitrated to 1000 mg b.i.d.)
Number of subjects: 0
Study 19173813 — intervention group
Group type: EXPERIMENTAL
Intervention: DNCE regimen
Number of subjects: 69
Study 19173813 — intervention group
Group type: COMPARATOR
Intervention: DICE regimen
Number of subjects: 69
Study 17086017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein (20 g/d)
Number of subjects: 30
Study 17086017 — intervention group
Group type: COMPARATOR
Intervention: Unmodified whey protein (control treatment)
Number of subjects: 30
Study 12675164 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine home visiting by public health nurses (PHN)
Number of subjects: 733
Study 12675164 — intervention group
Group type: COMPARATOR
Intervention: Screening telephone call
Number of subjects: 733
Study 10486435 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated tablet formulation of risedronate
Number of subjects: 25
Study 10486435 — intervention group
Group type: COMPARATOR
Intervention: Gelatin capsule formulation of risedronate
Number of subjects: 25
Study 1823735 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated heart rate-limited treadmill stress testing
Number of subjects: 96
Study 1823735 — intervention group
Group type: COMPARATOR
Intervention: Cinecoronary arteriography
Number of subjects: 96
Study 1823735 — intervention group
Group type: COMPARATOR
Intervention: Multivessel coronary artery disease
Number of subjects: 96
Study 1823735 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction
Number of subjects: 96
Study 7293955 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 0
Study 7293955 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 0
Study 6374946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube gastrostomy (Group G)
Number of subjects: 66
Study 6374946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric suction for 48 to 72 hours (Group NGS)
Number of subjects: 66
Study 6374946 — intervention group
Group type: EXPERIMENTAL
Intervention: No gastric decompression (Group ND)
Number of subjects: 66
Study 6374946 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group ND)
Number of subjects: 66
Study 6374946 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group NGS)
Number of subjects: 66
Study 30351426 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized antibiotic strategies (COMPASS)
Number of subjects: 0
Study 30351426 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART COMPASS
Number of subjects: 0
Study 30672198 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut moxibustion
Number of subjects: 67
Study 30672198 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate eye drops
Number of subjects: 67
Study 26846336 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language diabetes self-efficacy scale (DSES-S)
Number of subjects: 0
Study 26846336 — intervention group
Group type: EXPERIMENTAL
Intervention: English-language diabetes self-efficacy scale (DSES)
Number of subjects: 0
Study 26846336 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods designed to enhance self-efficacy (treatment)
Number of subjects: 0
Study 26846336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25231491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 or 1 mg/kg)
Number of subjects: 600
Study 25231491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 23257482 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom‐made resin post + Self‐etch adhesive
Number of subjects: 40
Study 23257482 — intervention group
Group type: COMPARATOR
Intervention: Glass FRC post + Self‐etch adhesive
Number of subjects: 40
Study 23257482 — intervention group
Group type: COMPARATOR
Intervention: Custom‐made resin post + Etch and Rinse adhesive
Number of subjects: 40
Study 23257482 — intervention group
Group type: COMPARATOR
Intervention: Glass FRC post + Etch and Rinse adhesive
Number of subjects: 40
Study 20122421 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon MX self-ligating brackets
Number of subjects: 70
Study 20122421 — intervention group
Group type: COMPARATOR
Intervention: In-Ovation R self-ligating brackets
Number of subjects: 70
Study 17631326 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 210
Study 17631326 — intervention group
Group type: COMPARATOR
Intervention: Observation (control for group 1)
Number of subjects: 210
Study 17631326 — intervention group
Group type: COMPARATOR
Intervention: Intravesical therapy (control for group 2)
Number of subjects: 210
Study 16239360 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 0
Study 12059939 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol containing sealer (Kerr Pulp Canal Sealer)
Number of subjects: 64
Study 12059939 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealer (AH‐26)
Number of subjects: 64
Study 12059939 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide sealer (Sealapex)
Number of subjects: 64
Study 12059939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not obturated)
Number of subjects: 64
Study 9952053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 570
Study 7817931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 110
Study 7817931 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 110
Study 7817931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (alternate therapy group)
Number of subjects: 110
Study 7817931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (overall efficacy)
Number of subjects: 110
Study 7817931 — intervention group
Group type: COMPARATOR
Intervention: Sotalol and Procainamide
Number of subjects: 110
Study 7817931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (follow-up)
Number of subjects: 110
Study 7817931 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (follow-up)
Number of subjects: 110
Study 2266432 — intervention group
Group type: COMPARATOR
Intervention: Cross-covering senior resident (CC group)
Number of subjects: 146
Study 2266432 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary senior resident (PE group)
Number of subjects: 146
Study 543911 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (Baypen) at a daily dosage of 2 x 5 g or 3 x 5 g
Number of subjects: 44
Study 31577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active community-wide screening for pulmonary tuberculosis using rapid nucleic acid amplification testing annually for 3 years.
Number of subjects: 83630
Study 31577876 — intervention group
Group type: COMPARATOR
Intervention: Standard passive case detection alone (control group).
Number of subjects: 83630
Study 31577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active community-wide screening for tuberculosis infection in children born in 2012.
Number of subjects: 83630
Study 28397833 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate
Number of subjects: 55
Study 28397833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 26952142 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized extract of Prunus mume (150 mg)
Number of subjects: 45
Study 24391490 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow model-free strategy
Number of subjects: 0
Study 24391490 — intervention group
Group type: EXPERIMENTAL
Intervention: General model-based strategy
Number of subjects: 0
Study 21940716 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (injection and capsules)
Number of subjects: 0
Study 18198986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment for 3 months
Number of subjects: 11
Study 18198986 — intervention group
Group type: COMPARATOR
Intervention: Control group (lean healthy women)
Number of subjects: 11
Study 18198986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia during the clamp
Number of subjects: 11
Study 18198986 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 11
Study 17504997 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676 (CpG B-type oligodeoxynucleotide)
Number of subjects: 23
Study 17504997 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%)
Number of subjects: 23
Study 15188947 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg U/day of Ultrasome-CoQ10 for 3 months
Number of subjects: 32
Study 15188947 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 32
Study 11151290 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only treatment group
Number of subjects: 252
Study 11151290 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 252
Study 9343478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptylin
Number of subjects: 367
Study 9343478 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 367
Study 9343478 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated treatment based on clinical sleep disturbances (including amitriptylin, imipramine, diazepam, nootropic drugs)
Number of subjects: 367
Study 8409069 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 88
Study 8409069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (digoxin withdrawal)
Number of subjects: 88
Study 3537823 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl treatment
Number of subjects: 100
Study 31464623 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice short message service (SMS) on malaria prevention, once a week for twelve months
Number of subjects: 332
Study 31464623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 332
Study 31464623 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect at endline
Number of subjects: 332
Study 31464623 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline treatment effect
Number of subjects: 332
Study 31464623 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention effect
Number of subjects: 332
Study 28249230 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent panel intervention targeting discussions about future opportunities and responses to academic difficulty
Number of subjects: 0
Study 28249230 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25588410 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife oral assessment and referral to private/public/health fund dental services pathway (Intervention Group 1)
Number of subjects: 0
Study 25588410 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife oral assessment and referral to local free public dental services pathway (Intervention Group 2)
Number of subjects: 0
Study 25588410 — intervention group
Group type: COMPARATOR
Intervention: Oral health promotional material only (Control Group)
Number of subjects: 0
Study 22885010 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (BI) for multi-substance use
Number of subjects: 853
Study 22885010 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster sessions
Number of subjects: 853
Study 22885010 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 853
Study 21672049 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ng/ml tacrolimus
Number of subjects: 26
Study 21672049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18638594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 70
Study 18638594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 70
Study 18638594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16501756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach without nicotine replacement therapy (GB)
Number of subjects: 1199
Study 16501756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 1 or 2 sessions (G1-G2) without NRT
Number of subjects: 1199
Study 16501756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 3 or 4 sessions (G3-G4) without NRT
Number of subjects: 1199
Study 16501756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with nicotine replacement therapy (GBA)
Number of subjects: 1199
Study 16501756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 1 or 2 sessions (G1A-G2A) with NRT
Number of subjects: 1199
Study 16501756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach with 3 or 4 sessions (G3A-G4A) with NRT
Number of subjects: 1199
Study 12547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25-100 mg)
Number of subjects: 188
Study 12547849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 10695262 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (attending classes at least twice a week for 25 weeks, each lasting two hours)
Number of subjects: 65
Study 10695262 — intervention group
Group type: COMPARATOR
Intervention: Control group (attending recreational classes twice a month)
Number of subjects: 65
Study 9359554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta blockers
Number of subjects: 12
Study 8096545 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dose of ebastine syrup
Number of subjects: 20
Study 8096545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of ebastine syrup
Number of subjects: 20
Study 3805797 — intervention group
Group type: COMPARATOR
Intervention: Regimen I (WHO 1982 recommendations: Dapsone and six once a month rifampicin)
Number of subjects: 80
Study 3805797 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II (Dapsone, rifampicin, and clofazimine 100 mg on alternate days)
Number of subjects: 80
Study 31501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted VAT mass
Number of subjects: 0
Study 31501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat
Number of subjects: 0
Study 31501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (in females)
Number of subjects: 0
Study 31501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (in males)
Number of subjects: 0
Study 29587805 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered recruitment strategies including trust, communication, attitude, and expectations.
Number of subjects: 743
Study 29587805 — intervention group
Group type: EXPERIMENTAL
Intervention: Active engagement and reminders at the offices.
Number of subjects: 743
Study 29587805 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone recruitment (site specific).
Number of subjects: 743
Study 28641216 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGASUS (8-session treatment)
Number of subjects: 179
Study 28641216 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 179
Study 24519767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy
Number of subjects: 390
Study 24519767 — intervention group
Group type: COMPARATOR
Intervention: Unilateral mastectomy
Number of subjects: 390
Study 24351088 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT with therapist support
Number of subjects: 150
Study 24351088 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT without therapist support
Number of subjects: 150
Study 24351088 — intervention group
Group type: COMPARATOR
Intervention: Active waiting list control group with delayed treatment
Number of subjects: 150